Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections

Expert Review of Vaccines

Volumn 10, Issue 3, 2011, Pages 345-353

  Zangeneh, Tirdad T ^a   Baracco, Gio ^a   Al Tawfiq, Jaffar A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b SAUDI ARAMCO   (Saudi Arabia)

Author keywords

pneumococcal vaccine; respiratory infection; vaccination

Indexed keywords

10 VALENT PNEUMOCOCCAL NONTYPABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MENINGITIS; MORTALITY; MULTIDRUG RESISTANCE; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEROTYPE; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 79953239762     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.1     Document Type: Review

References (74)

1. Adam D. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID. Brussels, Belgium June, 9-13, 2009. Vaccine 27(50), 7133-7137 (2009).
2. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines 8(10), 1351-1364 (2009).
3. CDC. Progress in introduction of pneumococcal cojugate vaccine worldwide. MMRW Morb. Mortal. Wkly Rep. 57(42), 1148-1151 (2008).
4. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. Expert Rev. Anti Infect. Ther. 7(9), 1063-1074 (2009).
5. Musher D. Streptococcus pneumoniae. In: Principles and Practice of Infectious Diseases (Volume 7). Mandell GL (Ed.). Churchill Livingstone Elsevier Publishers, PA, USA, 2623-2642 (2010).
6. Hirschmann J, Lipsky B. Pneumococcal vaccine in the United States: a critical analysis. JAMA 246(13), 1428-1432 (1981). Although an older study, this was one of the first papers published after the use of the pneumococcal polysaccharide vaccine and raised the issue of research needed to support widespread pneumococcal vaccination.
7. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization. Wkly Epidemiol. Rec. 82, 93-104 (2007).
8. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187-195 (2000).
9. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6), 403-409 (2001).
10. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25(12), 2194-2212 (2007).
11. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev. Vaccines 7(9), 1367-1394 (2008)
12. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 59(9), 258-261 (2010).
13. Dinleyici E, Zeynel A. Current knowledge regarding the investigational 13-valent pneumococcal vaccine. Expert Rev. Vaccines 977-986 (2009).
14. Liu Y, Wang H, Chen M et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn. Microbiol. Infect. Dis. 61(3), 256-263 (2008).
15. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46(2), 174-182 (2008).
16. O'Dempsey TJ, McArdle TF, Lloyd-Evans N et al. Pneumococcal disease among children in a rural area of West Africa. Pediatr. Infect. Dis. J. (5), 431-437 (1996).
17. Byington CL, Hulten KG, Ampofo K et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J. Clin. Microbiol. 48(2), 520-525 (2010).
18. CDC. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb. Mortal. Wkly Rep. 59(9), 253-257 (2010).
19. De Wals P, Black S, Borrow R, Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin. Ther. 31(10), 2152-2169 (2009).
20. Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr. Drugs 11(5), 349-357 (2009).
21. Knufa M, Habermehl P, Cimino C, Petersen G, Schmitt H. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24, 4727-4736 (2006).
22. CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb. Mortal. Wkly Rep. 57(13), 343-344 (2008).
23. Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368(9546), 1495-1502 (2006).
24. Schuchat A, Bell BP. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Rev. Vaccines 7(4), 437-456 (2008).
25. D'angio C, Heyne R, O'Shea T et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr. Infect. Dis. J. 29(7), 600-606 (2010).
26. Madhi S, Adrian P, Kuwanda L et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25(13), 2451-2457 (2007).
27. French N, Gordon S, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med. 362(9), 812-822 (2010).
28. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series. No. 927. WHO, Geneva, Switzerland (2005).
29. Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27(28), 3681-3688 (2009).
30. Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J. 24(2), 108-114 (2005).
31. Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr. Infect. Dis. J. 29(8), 756-762 (2010).
32. Pelton S, Weycker D, Klein J, Strutton D, Ciuryla V, Oster G. 7-valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine 28(6), 1575-1582 (2010).
33. Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine Pediatr. Infect. Dis. J. 28(4), S66-S76 (2009).
34. Dagan R, Frasch C. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction. Pediatr. Infect. Dis. J. 28(Suppl. 4), S63-S65 (2009).
35. Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol. 17(6), 1017-1026 (2010).
36. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5(3), 336-345 (1999). Elegantly describes serotype replacement using a mathematical model comparing the effects of the different levels of vaccine coverage, competitive interactions among pneumococcal serotypes and different vaccine types.
37. Aaberge I. Experience with pneumoccocal conjugate vaccine in Norway. Expert Rev. Vaccines 8(2), 159-165 (2009).
38. Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32-41 (2010).
39. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in massachusetts following universal immunization of infants with pneumococcal conjugate vaccine Pediatr. Infect. Dis. J. 26(6), 468-472 (2007).
40. Kaplan SL, Mason EO Jr, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine Pediatrics 125(3), 443-449 (2010).
41. Farrell D, Klugman K, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 26(2), 123-128 (2007).
42. Isaacman D, McIntosh E, Reinert R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 14(3), 197-209 (2010).
43. Mera R, Miller L, Fritsche T, Jone R. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 14(2), 101-107 (2008).
44. Long S. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine Clin. Microbiol. Infect. 41, 30-34 (2005).
45. Choi E, Kim S, Eun B, Kim S, Kim N, Lee J. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 271-281 (2008).
46. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199, 776-785 (2009).
47. Mera R, Miller L, Amrine-Madsen H, Sahm D. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb. Drug Resist. 15(4), 261-268 (2008).
48. Gertz RE, Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis. 201(5), 770-775 (2010).
49. Whitney C, Farley M, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N. Engl. J. Med. 348(18), 1737-1746 (2003).
50. Rodgers G, Arguedas A, Cohen R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27(35), 4739-4740 (2009).
51. Rodgers G, Arguedasb A, Cohenc R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27(29), 3802-3810 (2009).
52. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298(15), 1772-1778 (2007).
53. Grijalba CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118(3), 865-873 (2006).
54. Zhou F, Shefer A, Kong Y, Nuorti P. Trends in acute otitis media-related healthcare utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121(2), 253-260 (2008).
55. De Wals P, Carbon M, Sevin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 28(9), e271-e275 (2009).
56. Brook I, Gober A. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int. J. Pediatr. Otorhinolaryngol. 71(4), 575-579 (2007).
57. Mc Neil JC, Hulten, KG, Mason EO, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in children with chronic sinusitis. Pediatr. Infect. Dis. J. 28(9), 766-768 (2009).
58. Grijalva C, Nuort J, Arbogast P. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 1179-1186 (2007).
59. Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the 7-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 65, 770-774 (2010).
60. Rubin J, McGarry L, Klugman K, Strutton D, Gilmore K, Weinstein M. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect. Dis. 10(14), 3-11 (2010).
61. Klugman K, Chien Y, Madhi S. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 27(Suppl. 3), C9-C14 (2009).
62. Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes, and genotypes in Streptococcus pneumoniae over a thirty-year period. Clin. Microbiol. Infect. 16(5), 402-410 (2010).
63. Karnezis T, Smith A, Whittier S, Haddad J, Saiman L. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS ONE 4(6), e5965 (2009).
64. Kyaw M. Effect of Introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354(14), 1455-1466 (2006).
65. Dagan R, Klugman K. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 8(12), 785-795 (2008).
66. Harboe Z, Benfield T, Valentiner-Branth P et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin. Infect. Dis. 50(3), 329-337 (2010).
67. Jackson L, Janoff E. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis. 47(10), 1328-1338 (2008).
68. Obaro S. 7-valent pneumococcal conjugate vaccine for developing countries. Expert Rev. Vaccines 8(8), 1051-1061 (2009).
69. Hak E, Grobbee D, Sanders E et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth. J. Med. 66(9), 378-383 (2008).
70. Wong A, Marrie T, Garg S, Kellner J, Tyrrell G. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol. Infect. 138(12), 1804-1810 (2010).
71. Kieninger DM, Kueper K, Steul K et al. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healthy infants and toddlers. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. DC, USA, 25-28 October 2008.
72. Kieninger DM, Kueper K, Steul K et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28(25), 4192-4203 (2010).
73. GAVI's PneumoADIP. Surveillance and Research Report http://pneumoadip. idfive.com/pdf/Research-Surveillance-Report.pdf (Accessed 5 September 2010)
74. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, provisional-2009 www.cdc.gov/abcs/ reports-findings/survreports/spneu09.pdf (Accessed 20 November 2010)